The first person has received Moderna’s COVID-19 vaccine booster that targets the Omicron virus variant, the company announced Wednesday. The Phase 2 study is expected to enroll approximately 600 adults 18 or older, half of whom have received two doses of Moderna’s original vaccine and half of whom have received both the primary two-dose series and a…
Moderna Vaccinates First Participant in Trial of Omicron-Specific COVID-19 Booster
Omicron Evades mRNA Booster Protection, South African Study Shows
January 20, 2022
admin
AfricaCCP VirusInternationalModernamRNAOmicronPfizerSouth AfricastudyThe LancetVaccines & SafetyWorld
0 Comment
The Omicron variant of the novel coronavirus is able to evade the protection bestowed by messenger RNA (mRNA) COVID-19 vaccines, such as those from Pfizer and Moderna, a South African study has found. A study published Tuesday in The Lancet examined some of the first documented breakthrough cases of the highly transmissible Omicron strain, which emerged…
This Storage Unit Stock Has a Better 1-Year Return Than Microsoft, Apple, Starbucks and Moderna
Public Storage helps organize and store your belongings, and over the past year delivered astonishing returns. Since January 2021, Public Storage stock’s one-year return has outperformed several of the world’s most popular tech and growth stocks: Microsoft Corporation, Apple Inc., Wells Fargo & Co. and Moderna Inc.. Public Storage is a Glendale, California-headquartered REIT that primarily acquires, develops, owns and…
Moderna CEO Says Data for Omicron-Specific Shot Likely Available in March
January 18, 2022
admin
Business & EconomyCCP VirusCEOCompaniesdatamarchModernaOmicronStephane BancelUSUS NewsVaccineVaccines & Safety
0 Comment
Moderna Inc.’s vaccine candidate against the Omicron coronavirus variant will enter clinical development in the next few weeks and the company expects to be able to share data with regulators around March, CEO Stephane Bancel said on Monday. “The vaccine is being finished … it should be in the clinic in coming weeks. We are…
FDA Shortens Interval for Moderna COVID-19 Booster Based on Safety Data From Pfizer’s Booster Doses
January 7, 2022
admin
AMERICAbooster shotCCP VirusModernaModerna COVID-19 vaccinePUBLIC HEALTH INFORMATIONVaccines & Safety
0 Comment
The Food and Drug Administration’s (FDA) decision to shorten the interval time for Moderna’s COVID-19 vaccine to five months was based on scientific evidence that included the safety data from Pfizer’s booster shots given in Israel, the health regulator wrote in its authorization letter to Moderna. The health regulator announced Friday that it had amended…
FDA Shortens Time for Moderna’s COVID-19 Booster Dose
The Food and Drug Administration (FDA) on Friday revised the emergency use authorization for Moderna’s COVID-19 vaccine by shortening the period of time between receiving the initial two-dose vaccination and the booster shot by one month. For those aged 18 and older, the FDA now recommends that people receive the booster dose five months, instead…
Moderna CEO Claims People May Need 4th COVID-19 Shot in the Fall
January 7, 2022
admin
AMERICAboostersBusiness & EconomyBusinesses in COVID-19CCP VirusCOVID-19InternationalModernaUSUS NewsVaccineVaccines & SafetyWorld
0 Comment
Moderna’s Chief Executive Officer Stephane Bancel said on Thursday that people may need a fourth COVID-19 shot in the fall of 2022 due to the efficacy of third shots likely declining in the next several months. “I still believe we’re going to need boosters in the fall of ’22 and forward,” Bancel said at a…
Shares in COVID-19 Vaccine Developer Valneva Extend Fall
PARIS—Shares in biotech company Valneva fell again on Wednesday, declining for the seventh day in a row due to a growing belief amongst investors that the COVID-19 Omicron variant might lessen the need for mass vaccination. At 0945 GMT, Valneva shares were down 3 percent at 17.10 euros, meaning the stock has now lost close…
Young Men More Likely to Get Heart Inflammation After Pfizer’s Booster Than COVID-19: Study
Males under 40 years old are more likely to experience heart inflammation after getting a booster shot of Pfizer’s COVID-19 vaccine than COVID-19 itself, according to a recently published study. Males in the age group had a myocarditis incidence rate ratio of 7.6 in the 28 days following receipt of a Pfizer booster, researchers with…
Some Vaccinated Australian Seniors Remain Hesitant on Vaccine Safety
Among older Australians who have said they were overwhelmingly likely to get a COVID-19 vaccine, some are still raising concerns of vaccine safety and efficacy. COVID-19, the disease caused by the CCP (Chinese Communist Party) virus, has tragically led to the death of 2,168 Australians, 96 percent of whom were aged 50 and over. Currently,…
US News
RSS Error: A feed could not be found at `https://www.theepochtimes.com/c-us/feed`; the status code is `200` and content-type is `text/html; charset=utf-8`